Abstract:Background Human Papillomavirus (HPV) infection is a potential risk for cervical cancer, the latter is the fourth leading cause of cancer related death worldwide. Effective testing procedures are particularly important in its prevention and management. More accurate HPV tests replace traditional cytology based screening, and they are in line with national and international guidelines that recommend primary HPV testing due to its better efficacy. The purpose of the study was to confirm that these Gynius HPV detection kits were equal in efficiency compared with Roche Cobas HPV assay based testing, which could better facilitate earlier detection and stratification by risk level for cervical lesions. Methods The prospective parallel control study recruited 1000 women from the district hospitals of Kibagabaga and Muhima in Rwanda. Participants were tested for HPV DNA tests using both Roche and Gynius kits and then the samples were sent to Rwanda National Reference Laboratory. We analyzed the concordance of two Gynius variants (liquid and lyophilized ) and Roche across for several different HPV subtypes, such as 16, 18 or other high risk types (31,33,35,39,45,51,52,56,58,59,66,68,73,53,82 &26). Statistics like sensitivity, specificity, predictive values and consistency (Kappa) were calculated to compare the concordance of assays. Results We found that the Gynius HPV solution is exceptionally easy to implement in laboratory settings within low and middle income countries (LMICs). It offers effective sampling control through color detection, making it highly suitable for self sampling procedures. Additionally, the Gynius HPV solution includes an automated extraction system that completes full plate extraction in under 20 minutes. The Gynius solution is compatible with various qPCR systems, eliminating the need for costly qPCR machine repurchases. Using lyophilized reagents, which can be stored and transported at room temperature, it bypasses the need for a cold chain and refrigeration. The Gynius solution also has a high sample processing capacity. For instance, using the BioRad CFX96, it can produce up to 1,200 results per day per machine; with the BioRad CFX384, it can generate up to 4,000 results per day making it ideal for large scale screening. In a comparison of 987 samples, high risk HPV detection rates were consistent across all three tests: Roche (20%), Gynius liquid (23%), and Gynius lyophilized (21%). Concordance analysis showed high agreement rates, with both Gynius kits achieving over 80% compatibility with Roche for detecting HPV 16, 18, and other virus subtypes. Conclusion This study provides compelling evidence for the efficacy of the Gynius HPV kits (both lyophilized and liquid formulations), which demonstrated high concordance rates with established assays for detecting high risk HPV genotypes, particularly HPV 16 and 18. Engineered specifically for low and middle income countries (LMICs), the Gynius HPV kits integrate innovative sampling and detection technologies optimized for resource limited settings, facilitating seamless implementation. These findings indicate that Gynius HPV kits present a viable and scalable solution for cervical cancer screening programs, with the potential to significantly enhance early detection capabilities and broaden preventive care accessibility.

Analytic performance of ScreenFire HPV RS assay Zebra BioDome format and its potential for large-scale population HPV screening

Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource settings

A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study

Addressing cervical cancer screening disparities through advances in artificial intelligence and nanotechnologies for cellular profiling

Addressing Cervical Cancer Screening Disparities Through Advances in Artificial Intelligence and Nanotechnologies for Cellular Profiling.

AmpFire HPV and ScreenFire RS HPV validation trial

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology

Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening

A-251 Simplification of Molecular Diagnostics for Sexually Transmitted Infection Point-of-Care Testing

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.

Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?

Detection of 14 High-Risk Human Papillomaviruses Using Digital LAMP Assays on a Self-Digitization Chip

Improved Sensitivity of Vaginal Self-Collection and High-Risk Human Papillomavirus Testing.

Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention

An Injection Molded SlipChip with Self‐Sampling for Integrated Point‐of‐Care Testing of Human Papilloma Virus

Evaluation of the Allplex HPV assay's adherence to international guidelines for cervical cancer screening in clinician-collected samples

Intra‐ and interlaboratory reproducibility evaluation toward international validation status of the AmpFire assay

Abstract 6082: Rapid on-site nucleic acid detection using CRISPR and digital signal processing for portable and integrated cervical cancer screening in low resource settings

Assessment of Accuracy and Reliability: Validation trial for a Fluorescent Probe-Based Real-Time PCR Assay Kit in Detecting Human Papillomavirus Nucleic Acid

A New Pcr-Based Mass Spectrometry System For High-Risk Hpv, Part Ii Clinical Trial

CLIA Validation of a New High Performance HPV ctDNA Assay Covering Multiple High Risk HPV Types